NEW YORK, Jan 26, 2026, 3:17 p.m. ET — Regular session
- Pfizer shares climbed roughly 0.7% in afternoon trading, following the broader rise across U.S. stocks
- Ahead of Pfizer’s Feb. 3 earnings and the Fed’s upcoming decision, investors are adjusting their positions
- Attention centers on Pfizer’s ability to maintain profit and cash flow in 2026 amid waning COVID demand and patent challenges on older medications
Pfizer shares climbed 0.7% to $25.84 in afternoon trading Monday, bouncing between $25.60 and $25.89 earlier. The stock had closed at $25.65 previously.
The rally kicked off as U.S. stocks climbed ahead of a week loaded with mega-cap earnings and a key Federal Reserve policy update. “Investors are cautiously optimistic and most likely looking forward to earnings season,” said Chris Zaccarelli, chief investment officer at Northlight Asset Management. (Reuters)
The Fed’s meeting wraps up Wednesday, with the decision under a sharper lens amid renewed doubts about the central bank’s independence. Tim Duy, chief U.S. economist at SGH Macro Advisors, noted, “It’s not possible to view the actions of the next Fed chair as separate from the economic environment.” (Reuters)
Pfizer’s next major event is set for Feb. 3, when it will hold a webcast at 10 a.m. ET to go over its fourth-quarter 2025 results. (Pfizer Investor Relations)
Investors are keenly awaiting any updates to the 2026 forecast, after Pfizer in December set its revenue target between $59.5 billion and $62.5 billion, with adjusted diluted EPS expected to range from $2.80 to $3.00. (Pfizer)
The guidance hit hard, leaving Pfizer’s shares stuck in the mid-20s range. Analysts say the stock won’t move much until there’s a clearer growth story. “This stock is unlikely to break out of its current mid-20s price range until investors are convinced of a growth trajectory,” Bernstein analyst Courtney Breen told Reuters. (Reuters)
The Reuters report noted Pfizer’s forecast factors in a roughly $1.5 billion decline in COVID product revenue, along with another $1.5 billion impact from products going off-patent in 2026, partially balanced by planned cost reductions. (Reuters)
Income investors are watching Pfizer’s dividend schedule closely. The $0.43 quarterly payout went ex-dividend on Jan. 23, with the payment set for March 6, per the company’s investor page. (Pfizer Investor Relations)
Monday’s rally felt more like traders adjusting positions than responding to new Pfizer updates. By mid-afternoon, volume hovered around 27 million shares—well shy of what Pfizer usually sees on big news days.
Feb. 3 could stir up more caution than Wall Street is ready for, particularly regarding how quickly new launches can offset patent expirations and weaker COVID demand. Any tougher stance on margins or research spending might weigh on a stock that’s relied heavily on its dividend to attract investors.
The macro backdrop matters too. Should rates shift or the Fed’s signals unsettle investors this week, high-yield defensives such as major drugmakers could act like bond proxies—sometimes benefiting, sometimes not.
Up next: Wednesday’s Fed statement, followed by Pfizer’s Feb. 3 earnings and call — the first real opportunity this year for management to either reset expectations or stick to the script.
